MariMed Inc.

CNSX:MRMD Stock Report

Market Cap: CA$67.5m

MariMed Past Earnings Performance

Past criteria checks 0/6

MariMed has been growing earnings at an average annual rate of 44.1%, while the Pharmaceuticals industry saw earnings growing at 45.6% annually. Revenues have been growing at an average rate of 26.3% per year.

Key information

44.1%

Earnings growth rate

55.5%

EPS growth rate

Pharmaceuticals Industry Growth23.1%
Revenue growth rate26.3%
Return on equity-16.2%
Net Margin-9.0%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How MariMed makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

CNSX:MRMD Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24158-14600
30 Jun 24156-17580
31 Mar 24152-17550
31 Dec 23149-16510
30 Sep 23146-1490
30 Jun 231416450
31 Mar 231379430
31 Dec 2213413430
30 Sep 221292440
30 Jun 221292460
31 Mar 221287430
31 Dec 211217390
30 Sep 2111118290
30 Jun 219117220
31 Mar 21689190
31 Dec 20512170
30 Sep 2036-80500
30 Jun 2033-89480
31 Mar 2050-84480
31 Dec 1946-81460
30 Sep 1944-10160
30 Jun 1936-7150
31 Mar 1913-12130
31 Dec 1812-14120
30 Sep 1810-770
30 Jun 188-460
31 Mar 187-350
31 Dec 176-140
30 Sep 176030
30 Jun 175020
31 Mar 174020
31 Dec 164010

Quality Earnings: MRMD is currently unprofitable.

Growing Profit Margin: MRMD is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: MRMD is unprofitable, but has reduced losses over the past 5 years at a rate of 44.1% per year.

Accelerating Growth: Unable to compare MRMD's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MRMD is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-51.1%).

Return on Equity

High ROE: MRMD has a negative Return on Equity (-16.2%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/03 06:49
End of Day Share Price 2024/12/30 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

MariMed Inc. is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jonathan DeCourceyBTIG
Andrew SempleVentum Financial Corp